Supply Chain Archives
10/28/2025
Built or Bought? Why Biotechs are Outsourcing Supply Chain Infrastructure
For companies developing advanced therapy medicinal products (ATMPs), building an in-house end-to-end supply chain may seem like the ultimate sign of maturity. But in today’s resource-constrained market, biotech leaders are increasingly asking themselves whether it’s better to build, or to buy. From startups operating on limited funding to global biopharma players scaling into new markets, outsourcing supply chain infrastructure is becoming more than just a cost saving tactic. By partnering with specialized providers, developers gain instant access to global networks, regulatory expertise and compliance, and technical capabilities that would take years and significant capital to build internally.
10/08/2025
Resilience by Design: Lessons from Real-World Disruption
When it comes to Advanced Therapy Medicinal Products (ATMPs), disruption isn’t an “if,” it’s a “when.” When you’re dealing with unpredictable situations like geopolitical instability, sudden site closures, supply chain bottlenecks, or even weather-related delays, any disruption can potentially jeopardize patient treatments that may be irreplaceable. For sensitive therapies like these with narrow viability windows and strict temperature requirements, even a small deviation in process can have outsized consequences. In her Beyond Biotech podcast interview with Labiotech, Alison Pritchard, VP of Business Development for EMEA at Cryoport Systems, explained why resilience is one of the most critical (but often overlooked) pillars of ATMP delivery.
10/01/2025
Cryoport Systems Redefines the Global Supply Chain with Launch of New Facility Near Paris, France
Cryoport Systems is thrilled to announce the grand opening of our revolutionary Global Supply Chain Center in Louvre, France. This cutting-edge campus is a one-stop location for end-to-end, temperature-controlled supply chain solutions and is designed to tackle the most complex challenges in the life sciences industry.
09/15/2025
What’s Slowing the Journey from Therapy to Patient? Inside the Operational Hurdles of ATMPs
As more advanced therapy medicinal products (ATMPs) move from clinical trials to commercial launch, the industry has reached a critical inflection point. The science is advancing, approvals are accelerating, but patients still face steep barriers to access. In her Beyond Biotech podcast interview with Labiotech, Alison Pritchard, VP of Business Development for EMEA at Cryoport Systems, outlined the operational realities that stand between innovation and patient benefit. These challenges span manufacturing capacity, cold chain infrastructure, site coordination, and regional complexity.
08/25/2025
What’s Next for ATMP Regulation in EMEA
For advanced therapy developers expanding into Europe, regulatory approval is just the beginning. Even after securing authorization from the European Medicines Agency (EMA), companies often find themselves mired in a patchwork of national rules, pricing hurdles, and even access delays. In her recent appearance on the Beyond Biotech podcast by Labiotech, Alison Pritchard, Vice President of Business Development for Cryoport Systems in EMEA, pulled back the curtain on what it really takes to bring advanced therapies to patients across the region.
08/04/2025
ATMP Development in 2025: Promise, Pressure, and the Push to Scale
As the advanced therapy medicinal products (ATMP) sector reaches the midpoint of 2025, there’s no shortage of scientific momentum. Groundbreaking CRISPR-based therapies are making headlines. Patient access to cell and gene therapies is expanding beyond early adopter markets. And a maturing global regulatory environment is slowly but surely creating new opportunities for commercialization. But alongside this promise comes pressure.
03/24/2025
Strengthening Global ATMP Logistics: How Cryoport Systems’ Netherlands Facility Supports Temperature-Controlled Supply Chains
The success of ATMPs depends on more than just scientific breakthroughs, it requires a highly controlled, risk-mitigated supply chain that ensures product integrity from research through commercialization. With cell and gene therapies moving across multiple clinical sites, manufacturing facilities, and regulatory jurisdictions, developers need a logistics partner that can support seamless, temperature-controlled supply chain management at a global scale.
03/21/2025
Strengthening ATMP Development in Europe: How BioServices Centers in France Enable Efficiency and Scalability
As Advanced Therapy Medicinal Product (ATMP) developers progress from early-stage research to late-phase clinical trials and commercialization, biostorage, sample management, and regulatory-compliant logistics become increasingly complex. Efficiently managing these critical components is essential to ensure product integrity, regulatory compliance, and seamless supply chain operations.
03/21/2025
